The use of genome editing in early embryos has pulled back the curtain on the role of one of the key genes that orchestrates ...

The inventor of the groundbreaking Crispr gene-editing technology is skeptical about artificial intelligence replacing human ...

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.

A 23-year-old man from Louisiana has become one of the first people in the United States to be functionally cured of sickle ...

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing "copilot" ...

The surge in CRISPR-related scientific advances is reflected in the sharp increase in patent applications, particularly in the United States and China. Notably, many Chinese filings focus on ...

In a groundbreaking fusion of artificial intelligence and gene editing, researchers are leveraging machine learning to enhance CRISPR technology’s precision and efficiency. This integration is opening ...

In 2020, Jennifer Doudna won the Nobel Prize in chemistry for her work on the CRISPR-Cas9 gene-editing technology that allows ...

Antimicrobial resistance (AMR) is continuing to increase globally, with rates of AMR in most pathogens increasing and threatening a future in which every day medical procedures may no longer be ...

The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

CRISPR Therapeutics (NasdaqGM:CRSP) filed a large shelf registration, creating capacity to issue new securities over time.